arXiv:2608. 19436v1 Announce Type: cross Abstract: Alzheimer's disease (AD) progresses as a continuous biological process, whereas most existing neuroimaging-based artificial intelligence methods remain limited to discrete diagnosis or clinical score prediction from cross-sectional imaging.
arXiv:2606. 02228v1 Announce Type: cross Abstract: Predicting whether an individual with Alzheimer's disease will experience mild or severe disease progression is essential for personalized treatment.
arXiv:2606. 15784v1 Announce Type: new Abstract: Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade.
Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade. However, most longitudinal models represent this cascade either as a fixed sequence of biomarkers or as a black-box forecasting task.
arXiv:2606. 24604v1 Announce Type: new Abstract: Longitudinal modelling of Alzheimer's disease progression is clinically useful only if it can describe not just the most likely next diagnosis, but how a patient may evolve over time and how reliable that forecast is.
Longitudinal modelling of Alzheimer's disease progression is clinically useful only if it can describe not just the most likely next diagnosis, but how a patient may evolve over time and how reliable that forecast is. Most deep learning approaches reduce this problem to single-step classification, treating cognitively normal, mild cognitive impairment, and dementia as flat categories while providing limited insight into how uncertainty accumulates across future visits.
arXiv:2606. 09671v1 Announce Type: cross Abstract: Alzheimer's disease (AD) progression is highly heterogeneous and is typically observed through sparse and irregular longitudinal data, posing challenges for prediction and personalised monitoring.
arXiv:2607. 29530v1 Announce Type: new Abstract: Identifying reliable Alzheimer's disease (AD) markers typically requires manual, labor-intensive transcription and expert analysis, limiting its scale.
Alzheimer's disease (AD) progression is highly heterogeneous and is typically observed through sparse and irregular longitudinal data, posing challenges for prediction and personalised monitoring. Existing machine learning approaches have improved AD prediction using multimodal data, yet often focus on static classification or cohort-level risk estimation, providing limited support for subject-specific modelling and uncertainty-aware reasoning.
In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits. Integrating these multimodal observations may improve diagnostic assessment, but naive fusion can degrade performance when MRI is noisy or intermittently unavailable.
The paper introduces a reverse spatio‑temporal disease progression model that reconstructs unobserved healthier anatomy from later diseased scans. It employs a two‑stage architecture: a frozen 3D vector‑quantised autoencoder creates a discrete latent space, and a Neural ODE learns continuous‑time dynamics, with a recurrent encoder initializing the latent state from reverse‑ordered observations. Experiments on a synthetic Morpho‑MNIST benchmark and longitudinal Alzheimer’s MRIs show the model can recover unseen prior states and outperform baseline methods in predicting healthy trajectories.
arXiv:2607. 07091v1 Announce Type: cross Abstract: In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits.
arXiv:2512. 10966v3 Announce Type: replace-cross Abstract: Accurate and early diagnosis of Alzheimer's disease (AD) is critical for effective intervention and requires integrating complementary information from multimodal neuroimaging data.